A: An internist or infectious diseases specialist will treat cryptococcal meningitis. A: Cryptococcal paradoxical IRIS (immune reconstitution inflammatory syndrome) is a complication that arises after ...

-The PLATFORM-CM trial is evaluating oteseconazole and other investigational products against the standard of care for treating cryptococcal meningitis "We are excited to initiate this important study ...

Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases. A new, ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Nelesh P. Govender currently receives funding from the National Institutes of Health and US Centers for Disease Control and Prevention. South Africa has launched the world’s largest national screening ...

A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has entered Phase II clinical trials in Malawi and ...

Cryptococcus neoformans commonly causes opportunistic infection in immunocompromised patients, especially in patients with AIDS. The CD4+ T-lymphocyte count is measured in patients with HIV infection, ...

Crytococcal meningitis is a deadly invasive fungal infection which affects hundreds of thousands of HIV patients in the late stage of their disease every year. Crytococcal meningitis is a deadly ...

Scientists have captured video footage of meningitis as it spreads through a brain. Experts used transparent fish to watch in real-time as Cryptococcal meningitis spread through the organ. The ...

As a result of a large randomized, controlled trial (and experience during the first 15 years of the AIDS epidemic), standard guidelines for treatment of cryptococcal meningitis recommend 2 weeks of ...

A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.

Dar es Salaam / Lilongwe / Geneva — 15 April 2025 — A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has ...